HanAll initiate Phase I trial for oral formulation of human growth hormone

Published: 2011-10-10 06:56:00
Updated: 2011-10-10 06:56:00
HanAll BioPharma Co. said Thursday it has initiate Phase I trial in Seoul National University Hospital for orally available protease resistant human growth hormone (HL-032).

This clinical study is designed to compare the safety of efficacy of HL-032 and Pfizer’s Genotropin injection in four gr...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.